PCSA Stock Analysis: Buy, Sell, or Hold?
PCSA - Processa Pharmaceuticals, Inc. Common
$2.43
-0.07 (-2.80%)
âŧ
5d:
-5.45%
30d:
+8.48%
90d:
-20.85%
WAIT
LOW Confidence
Analysis Updated: Aug 14, 2026 12:00 AM ET
Earnings: Aug 20, 2026
2d
Get Alerted When PCSA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: PCSA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: PCSA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: PCSA is currently trading at $2.43, which is considered fair relative to its 30-day fair value range of $2.10 to $2.63.
Technical Outlook: Technically, PCSA is in a downtrend. Immediate support is located at $2.05, while resistance sits at $2.79.
Market Sentiment: PCSA scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $25.00 (+900.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PCSA is in a downtrend. Immediate support is located at $2.05, while resistance sits at $2.79.
Market Sentiment: PCSA scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $25.00 (+900.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.10 -
$2.63
Company Quality Score
33/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 900.0% below Wall St target ($25.00)
- WARNING: Composite score 33/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.10 -
$2.63
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$2.05
Resistance Level
$2.79
Current Trend
Downtrend
Technical data as of
Aug 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.67
Wall Street Target
$25.00
(+900.0%)
Share & Embed Analysis
Last updated: August 17, 2026 7:03 AM ET
Data refreshes hourly during market hours. Next update: 8:03 AM
Data refreshes hourly during market hours. Next update: 8:03 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PCSA showing a specific setup today?
Insider Activity (6 Months)
12
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
David Young
BUY
1545 shares
2026-04-15
George K Ng
BUY
1843 shares
2026-04-15
Russell Skibsted
BUY
1984 shares
2026-04-15
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 41 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$125 | 49 HOLD |
|
RNA
Atrium Therapeutics, IncâĻ |
STRONG BUY
15 analysts |
$25 | 43 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 67 BUY |
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
13 analysts |
$19 | 55 HOLD |
